Agios Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

• Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly adjusted loss of $2.42​​ per share for the quarter ended January 1, lower than the same quarter last year, when the company reported EPS of $-1.64. The mean expectation of ten analysts for the quarter was for earnings of $1.11 per share. Wall Street expected results to range from $-1.85 to $12.42 per share.

• Revenue rose 21.2% to $8.96 million from a year ago; analysts expected $9.46 million.

• Agios Pharmaceuticals Inc's reported EPS for the quarter was $16.22​.

• The company reported quarterly net income of $947.92 million.

• Agios Pharmaceuticals Inc shares had risen by 4.2% this quarter and gained 107.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 209.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $56.00

This summary was machine generated from LSEG data November 1 at 03:32 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)